PCSK9 inhibitors safe, effective for familial hypercholesterolaemia
A meta-analysis of 1,526 patients showed that proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors are safe and effective compared with placebo at reducing LDL-cholesterol (LDL-C) in patients with familial hypercholesterolaemia (FH). [Singh A, et al, AHA 2017, abstract QCOR06]
Researchers from Brigham and Women’s Hospital in Boston, Massachusetts, US, included patients with FH from eight trials that compared PCSK9 inhibitors with standard therapy for at least 12 weeks of follow-up.
Treatment with PCSK9 inhibitors resulted in a mean 48.06 percent reduction in LDL-C compared with placebo.
Besides LDL-C, PCSK9 inhibitors were associated with the largest percent change in non–HDL-cholesterol, followed by apolipoprotein B, total cholesterol, lipoprotein (a), and triglycerides. HDL-cholesterol and Apolipoprotein A1 showed smaller percent increases.
“PCSK9 inhibitors were safe and well tolerated, with injection site reactions being the most common adverse effect,” the researchers said.